Literature DB >> 2661287

Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide.

R Komatsu1, T Matsuyama, M Namba, N Watanabe, H Itoh, N Kono, S Tarui.   

Abstract

We examined the effect of glucagonlike peptides (GLPs), which are cleaved from preproglucagon in the enteroglucagon cells, on rat endocrine pancreas with the isolated perfused system. GLP-I-(7-36)-amide, a truncated form of full-sequence GLP-I-(1-37), showed a potent inhibitory effect on glucagon secretion. This inhibitory effect of GLP-I-(7-36)-amide was demonstrated at concentrations of 0.25, 2.5, and 25 nM in 11.2 and 2.8 mM glucose. In contrast, insulin release was significantly stimulated by GLP-I-(7-36)-amide at its concentration from 0.025 to 25 nM in a high glucose concentration, whereas in a low glucose concentration, the stimulation was seen only at the highest concentration (25 nM). Neither GLP-I-(1-37) nor GLP-II showed any effect on glucagon and insulin release. Although several gastrointestinal hormones have been nominated as incretins, none of them may suppress the glucagon secretion. A truncated form of GLP-I, GLP-I-(7-36)-amide thus seems to be a unique incretin that exerts glucagonostatic action.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2661287     DOI: 10.2337/diab.38.7.902

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  49 in total

1.  Truncated and full-length glucagon-like peptide-1 (GLP-1) differentially stimulate intestinal somatostatin release.

Authors:  P L Brubaker; S Efendic; G R Greenberg
Journal:  Endocrine       Date:  1997-02       Impact factor: 3.633

Review 2.  Cardiovascular impact of drugs used in the treatment of diabetes.

Authors:  Chris R Triggle; Hong Ding
Journal:  Ther Adv Chronic Dis       Date:  2014-11       Impact factor: 5.091

Review 3.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

4.  The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation.

Authors:  A Wettergren; M Wøjdemann; S Meisner; F Stadil; J J Holst
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

5.  Metabolic and endocrine functions of glucagon-like peptides - evolutionary and biochemical perspectives.

Authors:  T P Mommsen; E M Plisetskaya
Journal:  Fish Physiol Biochem       Date:  1993-07       Impact factor: 2.794

Review 6.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

7.  Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin.

Authors:  T Tolessa; M Gutniak; J J Holst; S Efendic; P M Hellström
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

8.  In vivo biological activity of exendin (1-30).

Authors:  Máire E Doyle; Patrick McConville; Michael J Theodorakis; Margaret M Goetschkes; Michel Bernier; Richard G S Spencer; Harold W Holloway; Nigel H Greig; Josephine M Egan
Journal:  Endocrine       Date:  2005-06       Impact factor: 3.633

9.  Potent inhibitory effects of transplantable rat glucagonomas and insulinomas on the respective endogenous islet cells are associated with pancreatic apoptosis.

Authors:  N Blume; J Skouv; L I Larsson; J J Holst; O D Madsen
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

10.  Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms.

Authors:  T Tolessa; M Gutniak; J J Holst; S Efendic; P M Hellström
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.